Navigator Medicine

Navigator Medicines is a clinical-stage biotechnology company focused on developing biologics for targeted immune regulation and restoration to treat complex autoimmune and inflammatory diseases. Founded in 2024 as a subsidiary of Sera Medicines, the company is headquartered in New Jersey and is backed by prominent investors including RA Capital Management and Forbion. Its lead program, NAV-240, is a bispecific antibody that simultaneously targets OX40L and TNFα, two clinically validated pathways in diseases like hidradenitis suppurativa and inflammatory bowel disease. Navigator is also advancing NAV-242, a next-generation bispecific with an extended half-life designed for optimized dosing and improved patient convenience. The company's pipeline was established through a significant in-licensing agreement with South Korean biotech IMBiologics, granting Navigator global rights to a portfolio of OX40L-targeted therapies. With a leadership team experienced in immunology drug development, Navigator aims to provide more durable and effective symptom relief for patients where current standards of care fall short.